Entities for cancer therapy

Details Entities for cancer therapy Entities for cancer therapy

C - Chemistry, Metallurgy

12

N

167/100, 167/202

C12N 15/52 (2006.01) A61K 38/45 (2006.01) A61K 38/46 (2006.01) A61K 38/48 (2006.01) A61K 38/50 (2006.01) A61K 48/00 (2006.01) C07H 19/06 (2006.01) C07H 19/16 (2006.01) C07H 21/00 (2006.01) C07K 14/765 (2006.01) C12N 9/12 (2006.01) C12N 15/11 (2006.01) C12N 15/85 (2006.01) C12N 15/867 (2006.01)

Patent

CA 2024253

Novel molecular chimaeras produced by recombinant BNA techniques are described. They comprise a target tissue specific transcriptional regulatory sequence (TRS) linked and controlling the expression of a heterologous enzyme for example Varicella Zoster Virus Thymidine Kinase (VZV TK) gene. A molecular chimaera is packaged into a synthetic retroviral particle which is capable of infecting mammalian tissue. This in turn may be administered to a patient, and the TRS will be selectively transcriptionally activated in the target tissue (for example cancerous tissue). Administration of compounds which are selectively metabolised by the enzyme produce cytotoxic or cytostatic metabolites in situ thereby selectively killing or arresting the growth of the target cell.

Affiliated with

Also associated with

Rating

Entities for cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Entities for cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Entities for cancer therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1523212